{
    "id": 23654,
    "fullName": "GLI2 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "GLI2 dec exp indicates decreased expression of the Gli2 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2736,
        "geneSymbol": "GLI2",
        "terms": [
            "GLI2",
            "CJS",
            "HPE9",
            "PHS2",
            "THP1",
            "THP2"
        ]
    },
    "variant": "dec exp",
    "createDate": "06/23/2016",
    "updateDate": "07/31/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7026,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, leukemia cells with reduced GLI2 and SHH mRNA levels were less sensitive to survival inhibition by GANT61 in culture (PMID: 26781311).",
            "molecularProfile": {
                "id": 24363,
                "profileName": "GLI2 dec exp SHH dec exp"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6046,
                    "pubMedId": 26781311,
                    "title": "Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26781311"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7013,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, leukemia cell lines with decreased levels of GLI2 and SHH mRNA were resistant to inhibition of survival by SANT1 in culture (PMID: 26781311).",
            "molecularProfile": {
                "id": 24363,
                "profileName": "GLI2 dec exp SHH dec exp"
            },
            "therapy": {
                "id": 3990,
                "therapyName": "SANT1",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6046,
                    "pubMedId": 26781311,
                    "title": "Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26781311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24362,
            "profileName": "GLI2 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24363,
            "profileName": "GLI2 dec exp SHH dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}